New drug CPO-100 tested in patients with advanced cancers

NCT ID NCT04931823

Terminated Disease control Sponsor: Conjupro Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 19, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
The Cleveland Clinic Foundation

Lyndhurst, Ohio, 44124, United States
University of California Los Angeles

Los Angeles, California, 75246, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
Virginia Cancer Specialist

Fairfax, Virginia, 22031, United States
Yale University School of Medicine - Yale Cancer Center

New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR